Alzheimer’s disease (AD) begins to alter and damage the brain years — even decades — before symptoms appear, making early identification of AD risk paramount to slowing its progression.
In a new study published online in the September 9, 2019 issue of the Neurobiology of Aging, scientists at University of California San Diego School of Medicine say that, with further developments, measuring how quickly a person’s pupil dilates while they are taking cognitive tests may be a low-cost, low-invasive method to aid in screening individuals at increased genetic risk for AD before cognitive decline begins.
In recent years, researchers investigating the pathology of AD have primarily directed their attention at two causative or contributory factors: the accumulation of protein plaques in the brain called amyloid-beta and tangles of a protein called tau. Both have been linked to damaging and killing neurons, resulting in progressive cognitive dysfunction.
The new study focuses on pupillary responses which are driven by the locus coeruleus (LC), a cluster of neurons in the brainstem involved in regulating arousal and also modulating cognitive function. Tau is the earliest occurring known biomarker for AD; it first appears in the LC; and it is more strongly associated with cognition than amyloid-beta. The study was led by first author William S. Kremen, PhD, and senior author Carol E. Franz, PhD, both professors of psychiatry and co-directors of the Center for Behavior Genetics of Aging at UC San Diego School of Medicine.
The LC drives pupillary response — the changing diameter of the eyes’ pupils — during cognitive tasks. (Pupils get bigger the more difficult the brain task.) In previously published work, the researchers had reported that adults with mild cognitive impairment, often a precursor to AD, displayed greater pupil dilation and cognitive effort than cognitively normal individuals, even if both groups produced equivalent results. Critically, in the latest paper, the scientists link pupillary dilation responses with identified AD risk genes.
“Given the evidence linking pupillary responses, LC and tau and the association between pupillary response and AD polygenic risk scores (an aggregate accounting of factors to determine an individual’s inherited AD risk), these results are proof-of-concept that measuring pupillary response during cognitive tasks could be another screening tool to detect Alzheimer’s before symptom appear,” said Kremen.
The Latest on: Diagnosing Alzheimer’s
via Google News
The Latest on: Diagnosing Alzheimer’s
- Potential new treatment targets for Alzheimer's diseaseon July 8, 2021 at 8:55 pm
Potential new treatment targets for Alzheimer disease as well as existing drugs that have therapeutic potential against these targets have been identified b ...
- Walk to End Alzheimer’s returning with new location Aug. 28on July 8, 2021 at 5:47 pm
... s Association of Colorado to continue to provide the essential programs and services for those who receive an Alzheimer’s diagnosis, as well as services for their family and caregivers. The 2021 ...
- 190K in Michigan live with Alzheimer’s. FDA taps brake on new drug.on July 8, 2021 at 1:54 pm
One month after its controversial approval by the FDA, the drug Aduhelm will be limited to just some of the 6.2M Americans — 190K in Michigan — who live with Alzheimer’s disease.
- Cure Alzheimer’s Fund Surpasses $125 Million In Research Fundingon July 8, 2021 at 9:21 am
We are honored to have been the recipients of the generosity of more than 50,000 donors who have made this research possible, and continue to work on behalf of the 50 million worldwide who have been ...
- New Alzheimer's treatment targets identifiedon July 8, 2021 at 8:00 am
A research team at Washington University School of Medicine in St. Louis has identified potential new treatment targets for Alzheimer's disease, as well as existing drugs that have therapeutic ...
- Amber Specialty Pharmacy to Dispense ADUHELM™ (aducanumab) for the Treatment of Alzheimer’son July 8, 2021 at 7:04 am
It is the 3rd leading cause of mortality in people over 65, behind cancer and heart disease. While Alzheimer’s disease is usually diagnosed in people 65 and older, it starts earlier with subtle ...
- The Difference Between Dementia and Alzheimer's, Explainedon July 8, 2021 at 6:30 am
Dementia and Alzheimer's both affect cognitive functioning and can interfere with daily life, but they're not the same.
- A New Alzheimer’s Drug Offers More Questions Than Answerson July 7, 2021 at 7:33 am
The approval of Aduhelm to treat Alzheimer’s disease has raised hope among older adults, but many doctors wonder if it is warranted.
- Linus Health raises $55M for early screening for Alzheimer’s diseaseon July 6, 2021 at 10:30 am
Linus Health has raised $55 million in funding for screening tools to diagnose dementia and Alzheimer's disease.
- Tony Bennett to Join Lady Gaga on MTV Unplugged 6 Months After Revealing His Alzheimer's Diagnosison June 30, 2021 at 12:10 pm
Tony Bennett is reuniting with Lady Gaga. Just months after his family revealed his Alzheimer's disease diagnosis to the public, the legendary musician, 94, is set to team up with the pop star and ...
via Bing News